Visualization of clot composition in ischemic stroke: Do we get what we see?

Stroke

Volumn 42, Issue 5, 2011, Pages 1193-1194

  Minnerup, Jens ^a   Kleinschnitz, Christoph ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

clot composition; early vessel signs; stroke

Indexed keywords

ACUTE DISEASE; BLOOD CLOT; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; STROKE; THROMBECTOMY; TREATMENT OUTCOME;

ANIMALS; BLOOD PLATELETS; ENDOVASCULAR PROCEDURES; ERYTHROCYTES; FIBRIN; HUMANS; LEUKOCYTES; MAGNETIC RESONANCE IMAGING; MODELS, ANIMAL; STROKE; THROMBECTOMY; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79955485054     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.612150     Document Type: Editorial

References (12)

1. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol. 1993;14:3-13. (Pubitemid 23055914)
2. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150. (Pubitemid 30126602)
3. Niessen F, Hilger T, Hoehn M, Hossmann KA. Differences in clot preparation determine outcome of recombinant tissue plasminogen acti-vator treatment in experimental thromboembolic stroke. Stroke. 2003;34: 2019-2024. (Pubitemid 36944800)
4. Jang IK, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79:920-928. (Pubitemid 19100552)
5. Kirchhof K, Sikinger M, Welzel T, Zoubaa S, Sartor K. Does the result of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in rabbits depend on the erythrocyte-and fibrin-content of a thrombus? [in German]. Rofo. 2004;176:98-105. (Pubitemid 38140993)
6. Kirchhof K, Welzel T, Mecke C, Zoubaa S, Sartor K. Differentiation of white, mixed, and red thrombi: value of CT in estimation ofthe prognosis of thrombolysis phantom study. Radiology. 2003;228:126-130. (Pubitemid 36736079)
7. Kimura K, Iguchi Y, Shibazaki K, Terasawa Y, Aoki J, Matsumoto N. The presence of a right-to-left shunt is associated with dramatic improvement after thrombolytic therapy in patients with acute ischemic stroke. Stroke. 2009;40:303-305.
8. Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, et al. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke. 2006;37:2086-2093. (Pubitemid 44309909)
9. Liebeskind DS, Sanossian N, Yong WH, Starkman S, Tsang MP, Moya BS, et al. CT and MRI early vessel signs reflect clot composition in acute stroke. Stroke. 2011;42:1237-1243.
10. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, et al. Infarcts ofundetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382-390. (Pubitemid 19104170)
11. Spuentrup E, Botnar RM, Wiethoff AJ, Ibrahim T, Kelle S, Katoh M, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008;18:1995-2005.
12. Uppal R, Catana C, Ay I, Benner T, Sorensen AG, Caravan P. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe\feasibility study in rat model. Radiology. 2010 Dec 21 [Epub ahead of print]